CRISPR-Edited T Cells Used in Cancer Patients for the First Time in the US

Emily Makowski in The Scientist:

Preliminary research suggests that using CRISPR to treat cancer is safe in humans and could become a feasible therapeutic method in the future, although its efficacy is still unknown. Results from an ongoing clinical trial, led by hematologist Edward Stadtmauer of the University of Pennsylvania Perelman School of Medicine, will be presented at the American Society of Hematology meeting in December. The presentation abstract was published online yesterday (November 5).

Stadtmauer’s team procured T cells from three cancer patients—two with multiple myeloma and one with sarcoma—through a blood draw, and genetically modified the cells’ DNA using CRISPR. They inserted a gene from a virus into the immune cells that causes the cells to target the protein NY-ESO-1, found on cancer cells, and deactivated three genes within the cells that could interfere with their cancer-fighting ability. Two of the gene edits inactivate TCRα and TCRβ, causing T cell receptors to be removed. Without the receptors, the the cells can more easily bind to cancer cells. The third edit disables PDCD1, a gene that can kill T cells. The researchers then infused the cells back into the patients, who have since had no significant adverse effects after six months, according to NPR. Research is still underway to determine whether the altered T cells are having any effect on the cancers, according to the The New York Times.

More here.